Overview Neoadjuvant L19IL2/L19TNF- Pivotal Study Status: Unknown status Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary Phase III, open-label, randomized, controlled multi-center study. In the study, 214 patients will be enrolled and parallel assigned (via randomization system) in a 1:1 fashion to one of two different arms. Phase: Phase 3 Details Lead Sponsor: Philogen S.p.A.